XELOX方案序贯希罗达单药维持治疗晚期胃癌的临床观察

目的观察XELOX方案序贯希罗达维持治疗晚期胃癌的临床疗效及不良反应，为晚期胃癌患者的维持治疗提供依据。方法45例晚期胃癌患者行4周期XELOX方案化疗后病情稳定者随机分为观察组（希罗达单药化疗）和对照组（停药观察），观察组行4周期化疗后评价疗效和不良反应。结果疗效评价：观察组CR2例（10％）、PR13例（65％）、SD3例（15％）、PD2例（10％）、RR15例（33．3％）、DCR18例（90％）；对照组CR0侧、PR4例（20％）、SD6例（30％）、PD10例（50％）、RR4例（20％）、DCR10例（50％），二组比较差异均有统计学意义（P〈0．05）；毒副反应：观察组的手足综合征发生率为75％，与对照组比较，差异有统计学意义（P〈0．05），二组在恶心呕吐、腹泻、骨髓抑制、口腔黏膜炎方面差异无统计学意义（P〉0．05）。结论晚期胃癌患者一线化疗后病情稳定者，给予希罗达单药维持治疗安全、有效、毒副反应少。

CLINICAL OBSERVATION OF XELOX CHEMOTHERAPEUTIC SCHEME FOLLOWED BY XELODA A- LONE IN MAINTENANCE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC CANCER

Objective To observe the efficacy and toxicity of xelox chemotherapeutic scheme followed by xeloda in maintenance treatment for patients with advanced gastric cancer. Methods Totally 45 patients with advanced gastric cancer, who had been carried out 4 cycles of xelox chemotherapeutic scheme and dis- ease had been controlled, were divided into maintenance treatment group （xeloda alone chemotherapy） and control group （ with drawl observation）, the efficacy and toxicity were observed in the treatment group af- ter 4 cycles of xloda chemotherapeutic scheme. Results Response evaluation： There was 2 （10%） com- plete remission （CR）, 13 （ 65 % ） partial remission （ PR）, 3 （15 % ） stable disease （SD） , 2 （ 10 % ） progres- sive disease （PD） in treatment group. The total response rate（RR） was 33.3%, the disease control rate （DCR） was 90% There were 0 complete remission （CR）, 4 （20%） partial remission {PR） ,6 （30%） sta- ble disease （SD）, 10 （50% ） progressive disease （PD） in control group. The total response rate （RR） was 20%, the disease control rate （DCR） was 10%, there were significantly different between the two groups （P〈0.05）. Toxicity： There was significantly difference in hand- loot syndrome incidence rate between the two groups（ P 〈0.05）, incidence of other side effects, such as nausea, diarrhea, bone marrow sup- pression, oral mucositis, were not significantly different between the two groups（P〈0.05） Conclusion Xeloda alone maintenance treatment shows good curative effects and few side effects in patients with ad- vanced gastric cancer who disease have been controlled after first- line chemotherapy.